Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The virus, known as HPgV-2, was detected in blood samples from individuals with concurrent hepatitis C virus infections.
The amendment changes product fees Abbott pays to BG Medicine for galectin-3 test sales in exchange for making two payments totaling $1 million.
The diagnostics manufacturer attributed the decline to the negative impact of foreign currency exchange and lower international sales.
Abbott's third quarter diagnostic revenues shrunk 2 percent and molecular diagnostics sales dropped 5 percent, both due to unfavorable currency effects.
With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
A number of firms now have FDA-approved Group A Strep assays, but end users may be hesitant to adopt them until Infectious Disease Society of America guidelines are updated.
The test runs on the firm's m2000 PCR platform and is the first on the market to assess resistance to both rifampin and isoniazid.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.